Topical Corticosteroid OTC Use Voted Down By Committee Due To Safety Risk
Executive Summary
Potentially fatal adverse events following "maximal use" of topical corticosteroids should preclude an Rx-to-OTC switch of the therapeutic class, a majority of FDA advisory panelists said March 24